Bone Marrow Mobilized with Granulocyte Colony-Stimulating Factor in Related Allogeneic Transplant Recipients: A Study of 29 Patients

Biology of Blood and Marrow Transplantation

Volumn 6, Issue 4 A, 2000, Pages 422-427

  Couban, Stephen ^a   Messner, Hans A ^b   Andreou, Pantelis ^a   Egan, Barbara ^a   Price, Sandra ^b   Tinker, Lisa ^b   Meharchand, Jacinta ^b   Forrest, Donna L ^a   Lipton, Jeffrey ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Aspiration; Engraftment; G CSF

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; ALLOTRANSPLANTATION; ARTICLE; BLOOD DISEASE; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; FEMALE; GRAFT SURVIVAL; HUMAN; MALE; MIDDLE AGED; STEM CELL MOBILIZATION;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; FEMALE; GRAFT SURVIVAL; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; MALE; MIDDLE AGED; TRANSPLANTATION, HOMOLOGOUS;

EID: 0034566409     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1083-8791(00)70033-4     Document Type: Article

References (24)

1. Schmitz N, Linch DC, Dreger P, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients. Lancet. 1996;347:353-357.
2. Korbling M, Przepiorka D, Hug YO, et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantages of blood over marrow allografts. Blood. 1995; 85:1659-1665.
3. Bensinger WI, Weaver CH, Appelbaum FR, et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood. 1995;85:1655-1658.
4. Schmitz N, Dreger P, Suttorp M, et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood. 1995; 85:1666-1672.
5. Couban S, Dranitsaris G, Andreou P, et al. Clinical and economic analysis of allogeneic peripheral blood progenitor cell transplants: a Canadian perspective. Bone Marrow Transplant. 1998;22:1199-1205.
6. Majolino I, Saglio G, Scimè R, et al. High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell (PBSC) transplantation in patients with hematologic malignancies [abstract]. Blood. 1995;86(suppl):108.
7. Solano C, Martinez C, Brunet S, et al. Chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors: a case-control study. Spanish Group of Allo-PBT. Bone Marrow Transplant. 1998;22:1129-1135.
8. Schmitz N, Bacigalupo A, Hasenclever D, et al. Allogeneic bone marrow transplantation versus filgrastim-mobilized peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomized multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1997;21:995-1003.
9. Couban S, Simpson DR, Bredeson C, et al. First 100 donors in the Canadian Bone Marrow Transplant Group trial comparing peripheral blood and bone marrow in allogeneic transplant [abstract]. Bone Marrow Transplant. 1998;21(suppl 1):S36.
10. Fyles GM, Messner HA, Lockwood G, et al. Long-term results of bone marrow transplantation for patients with AML, ALL and CML prepared with single dose total body irradiation of 500 cGy delivered with a high-dose rate. Bone Marrow Transplant. 1991;8:453-463.
11. + cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother. 1996;5:213-226.
12. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295-304.
13. Atkinson K, Horowitz MM, Gale RP, Lee MB, Rimm AA, Bortin MM. Consensus among bone marrow transplanters for diagnosis, grading and treatment of graft-versus-host disease. Committee of the International Bone MarrowTransplant Registry. Bone Marrow Transplant. 1989;4:247-254.
14. Johnson HE, Hansen PB, Plesner T, et al. Increased yield of myeloid progenitor cells in bone marrow harvested for autologous transplantation by pretreatment with recombinant human granulocyte-colony stimulating factor. Bone Marrow Transplant. 1992;10:229-234.
15. + cells. Prog Clin Biol Res. 1994;389:363-369.
16. Lowenthal RM, Sullivan JA, Parker N, Marsden KA. G-CSF-primed bone marrow cells for autologous transplantation [comment]. Lancet 1996;347:1125.
17. Hansen PB, Knudsen H, Gaarsdal E, Jensen L, Ralfkiaer E, Johnsen HE. Short-term in vivo priming of bone marrow haematopoiesis with rhG-CSF, rhGM-CSF or rhIL-3 before marrow harvest expands myelopoiesis but does not improve engraftment capability. Bone Marrow Transplant. 1995;16:373-379.
18. Sosman JA, Stiff PJ, Bayer RA, et al. A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy. Bone Marrow Transplant. 1995;16:655-661.
19. Meisenberg B, Frakes L, Brehm T, Schmeckel A, Miller W, McMillan R. Use of G-CSF given to allogeneic donors to improve CD34 yields in bone marrow collection and hasten engraftment [abstract]. Blood. 1996;88(suppl 1):403a.
20. Isola LM, Scigliano E, Skerrett D, et al. A pilot study of allogeneic bone marrow transplantation using related donors stimulated with G-CSF. Bone Marrow Transplant. 1997;20:1033-1037.
21. + cell content but is associated with delayed pancytopenia. Bone Marrow Transplant. 1998;21:431-440.
22. Bodine DM, Seidel NE, Orlic D. Bone marrow collected 14 days after in vivo administration of granolocyte colony-stimulating factor and stem cell factor to mice has 10-fold more repopulating ability than untreated bone marrow. Blood. 1996;88:89-97.
23. + colony-forming cell types in blood and marrow of baboons. Blood. 1992;80:920-927.
24. Tong J, Gordon MS, Srour EF, et al. In vivo administration of recombinant methionyl human stem cell factor expands the number of human marrow hematopoietic stem cells. Blood. 1993; 82:784-791.